Siltuximab for multicentric Castleman disease. Issue 5 (October 2014)

• Record Type: Journal Article
• Authors: Liu, Yi-Chang; Stone, Katie; van Rhee, Frits
• Is Part Of: Expert review of hematology. Volume 7:Issue 5(2014)
• Page Start: 545
• Page End: 557
• Publication Date: 2014-10
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1586/17474086.2014.946402
• Languages: English
• ISSNs: 1747-4086

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Dysregulated secretion of IL-6 plays a pivotal role in the pathogenesis of Castleman disease (CD), a rare lymphoproliferative disorder. In contrast to unicentric CD for which surgery is considered the treatment of choice, there is no standard therapeutic approach for multicentric CD (MCD). Siltuximab (trade name: Sylvant, formerly known as CNTO 328) is a chimeric monoclonal antibody with high binding affinity for human IL-6. In a recent randomized placebo-controlled Phase II trial, subjects with HIV-negative, HHV8-negative MCD who received siltuximab demonstrated a significantly higher rate of durable tumor and symptomatic response with a tolerable safety profile, leading to its approval for the treatment of HIV-negative HHV8-negative MCD by the US FDA and the European Commission in April and May 2014, respectively. This article will cover the current treatment options of MCD, the drug profile of siltuximab and future directions in the management of MCD.</p> </abstract>